OBJECTIVES The purpose of this study was to compare the 1-year outcome between bioresorbable vascular scaffold (BVS) and everolimus-eluting metallic stent (EES) in ST-segment elevation myocardial infarction (STEMI) patients.
T he ABSORB trials have shown the safety and feasibility of everolimuseluting bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, California) implantation in patients with stable angina or silent ischemia and with de novo nonthrombotic coronary artery lesions, with many physiological advantages of BVS over metallic prosthesis and a low rate of major adverse cardiovascular events up to 4-year follow-up (1, 2) .
The physiological advantages of BVS, such as late lumen enlargement and vasomotion, appear particularly appealing for the treatment of ST-segment elevation myocardial infarction (STEMI) (3) . Recent studies have shown short-term safety and feasibility of BVS implantation in STEMI patients (4, 5) .
However, those data are limited by lack of a control group, small sample size, and short-term follow-up.
In addition, some reports of scaffold thrombosis have recently raised concerns about actual BVS safety in a thrombotic milieu, such as STEMI, especially in light of the very low incidence of such events with secondgeneration drug-eluting metallic stents, reported in recent trials and meta-analyses (5) (6) (7) (8) (9) (10) .
We therefore conducted an analysis by matching consecutive STEMI patients receiving BVS at 6 centers with the cohorts of STEMI patients receiving Patients from the controlled EXAMINATION trial, randomized to Xience V or BMS, were used for matching with BVS patients (7) .
Percutaneous coronary intervention (PCI) was performed according to conventional clinical practice: manual thrombus aspiration, glycoprotein (GP) IIb/IIIa inhibitors, heparin, and bivalirudin administration were performed according to operator's choice. Balloon pre-dilation was not mandatory but was recommended for BVS implantation, according to BVS instructions for use. Dual antiplatelet therapy with aspirin plus clopidogrel, ticagrelor, or prasugrel was prescribed in all patients for 12 months. Of note, neither prasugrel nor ticagrelor were approved during the recruitment period of the EXAMINATION trial.
The investigators of each institution who participated in the study were asked to complete a struc- After propensity score matching, patient demographics were comparable between the matched groups, except for history of smoking, which was more prevalent in the BVS group.
RESULTS
With regard to procedural characteristics, the BVS and EES groups differ in the device implantation technique used, with higher use of pre-and postdilation in the BVS than in the EES group. Whereas pre-PCI Thrombolysis In Myocardial Infarction (TIMI) flow was lower in the BVS than in the EES group, no differences were found in post-PCI TIMI flow. A higher rate of GP IIb/IIIa inhibitor use was found in the BVS group than in the EES group. A higher rate of pre-and post-dilation was also found in the BVS than in the BMS group.
Whereas all EES and BMS patients were on aspirin and clopidogrel, BVS patients were taking clopidogrel (33.3%), ticagrelor (32.9%), or prasugrel (33.8%) in addition to aspirin. At 1 year, no differences were found between the 2 groups with regard to the DOCE (HR: 0.94 [95% confidence interval (CI): 0.23 to 4.32], p ¼ 0.994), even after adjustment for GP IIb/IIIa inhibitors and clopidogrel (HR: 1.50 [95% CI: 0.24 to 9.50], p ¼ 0.662) ( Table 2) . The DOCE was also not different between the BVS and EES groups at 30 days (HR: 1.31 [95% CI: 0.48 to 3.52], p ¼ 0.593) ( Figure 1A) . No differences were found in its individual components either at 30 days or 1 year ( Table 2) . One BVS thrombosis occurred in a patient with 2 BVS overlapped, who stopped the prescribed antiplatelet therapy (aspirin þ ticagrelor) 3 days before the event; no other patients with device thrombosis withdrew any antiplatelet agent ( Table 3) .
CLINICAL OUTCOMES BETWEEN BVS AND BMS.
Either at 30 days or at 1 year, no differences were found between the 2 groups ( Table 2) . Figures 1C and 1D show Kaplan-Meier curves for the DOCE and definite/ probable device thrombosis.
DISCUSSION
This is the first study comparing BVS versus EES versus BMS in STEMI patients, based on propensity score matching. The main findings of the present study can be summarized as follows. 1) The 30-day A lot of attention has been recently focused on BVS use in STEMI, as thrombotic lesions, which are most frequently thin-cap fibroatheromas, rich in necrotic core and covered by a thin fibrous cap (<65 mm), may represent the best scenario for the BVS "vascular restoration therapy" (14) . Autopsy studies suggested that metallic struts embedded in necrotic core may remain uncovered even in the long term and thus potentially be a trigger for stent thrombosis (15) .
Conversely, BVS, which in the long term are completely replaced by connective tissue and smooth muscle cells, may overcome the problem of metal persistence into the coronary vessel wall and may at the same time stabilize a thin-cap fibroatheroma with a neointimal layer (3). In addition, from a physiological perspective, the absence of permanent vessel caging facilitates the restoration of vasomotor function, adaptive shear stress, cyclic strain, and late lumen enlargement (14) .
The first few data published on BVS in acute coronary syndrome showed safety and feasibility of its implantation; however, all these reports were limited by lack of a randomized control group, very small sample size, and short-term follow-up (4, 16, 17) . In addition, some concerns have been recently raised on the high thrombogenicity of BVS in a thrombotic milieu, such as STEMI (5, 6, 18) . Given this background, our analysis collected individual data from 6
high-volume centers with large experience in BVS implantation in STEMI, allowing us to have the largest current cohort of STEMI treated by BVS.
By using a propensity score matching with STEMI treated by EES or BMS, a comparison of these therapeutic strategies was performed. In this regard, the EXAMINATION trial, which randomized 1,501 all-comer STEMI patients 1:1 to EES versus BMS, provided perfect controlled EES and BMS groups to build a propensity score (7) .
We be advocated to explain these findings, which in any case should be considered as hypothesis-generating and confirmed in future trials powered for this safety endpoint. In particular, a reduction in strut thickness, which will take place in the new BVS generation, will probably represent an important step forward in this regard.
In comparison with a previous large-scale ran- It is interesting to note that the higher use of balloon pre-dilation in the BVS group did not translate into an increase in distal embolization with 
